狂犬病ワクチンの世界市場

狂犬病ワクチンの世界市場は2030年までに16億米ドルに達する

2024年に13億米ドルと推定される狂犬病ワクチンの世界市場は、2030年には16億米ドルに達し、分析期間2024-2030年のCAGRは3.8%で成長すると予測されます。本レポートで分析したセグメントの1つであるニワトリ胚細胞狂犬病ワクチンは、CAGR 4.6%を記録し、分析期間終了時には7億800万米ドルに達すると予測されています。ヴェロ細胞狂犬病ワクチンセグメントの成長率は、分析期間中CAGR 3.9％と推定されます。

米国市場は3億4,770万米ドルと推定、中国はCAGR 7.2％で成長予測

米国の狂犬病ワクチン市場は、2024年に3億4,770万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを7.2%として、2030年までに3億2,480万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.5％と3.0％と予測されています。欧州では、ドイツがCAGR 2.2%で成長すると予測されています。

世界の「狂犬病ワクチン」市場- 主要動向と促進要因のまとめ

健康への脅威が続く中、「狂犬病ワクチン」市場が世界的に注目される理由とは？

狂犬病は、アジアとアフリカを中心に毎年5万9,000人以上の命を奪っており、最も致命的でありながら完全に予防可能な病気の一つです。100％ワクチンで予防可能であるにもかかわらず、報告不足、ヘルスケアへのアクセス制限、認識不足が、これまで十分な予防接種を妨げてきました。WHOやGAVIなどの政府、非政府組織、国際保健機関が、2030年までに犬を介した狂犬病によるヒトの死亡をなくすための取り組みを拡大するにつれて、世界の狂犬病ワクチン市場は注目を集めています。曝露前予防薬（PrEP）と曝露後予防薬（PEP）の両方に対する需要が高まっており、特に、犬に咬まれることが最も多い農村部やリスクの高い人々の間でその傾向が顕著です。認知度向上キャンペーンや犬へのワクチン接種の義務化は、感染率を向上させています。さらに、世界の旅行と観光の復活により、狂犬病流行地域を訪れる前にPrEPを必要とする旅行者が増え、新たな需要が生まれています。教育機関、動物愛護センター、動物病院は、地域保護における役割を認識し、狂犬病ワクチンの在庫を増やす傾向にあります。より広範なスケールでは、顧みられない熱帯病を対象とした公衆衛生資金が国の狂犬病対策プログラムに振り向けられ、ヒト用と動物用の狂犬病ワクチンの一貫した調達が推進されています。COVID-19以降、ペットの飼育が増加し、人獣共通感染症予防への関心が高まったことも、公衆衛生の優先事項としての狂犬病ワクチン接種の認知度を高め、長期的な市場拡大の舞台を整えました。

ワクチン技術の革新は狂犬病予防接種プログラムをどう変えるか？

メーカーが旧式の神経組織ワクチンから、精製ニワトリ胚細胞ワクチン（PCECV）やヒト二倍体細胞ワクチン（HDCV）のような、より高度な細胞培養ベースのワクチンへとシフトしているためです。これらの新しいワクチンは、免疫原性が改善され、副反応が少なく、投与量も少なくて済むため、最新の予防接種スケジュールに適合しやすくなっています。また、曝露後のプロトコールにおいて、従来の狂犬病免疫グロブリンに代わる、あるいは補助的な、即効性のあるモノクローナル抗体ベースの生物製剤の研究も進行中です。さらに、遠隔地や低資源環境におけるコールドチェーン物流の課題に対処するため、耐熱性ワクチン製剤が出現しつつあります。皮内投与やマイクロニードルパッチなど、針を使用しない送達方法は、使いやすさを向上させ、必要投与量を減らし、患者のコンプライアンスを高めるために試みられています。モバイルアプリやブロックチェーンによるワクチンの追跡・確認など、デジタルヘルスのイノベーションは、予防接種記録を合理化し、分散型予防接種キャンペーンにおけるモニタリングを改善しています。また、大手製薬企業は、より少ない注射回数で長期間の免疫を強化するアジュバント技術に投資しています。さらに、野生動物用の経口ベイトワクチンのような動物用狂犬病ワクチンの技術革新は、家畜のペット以外の駆除戦略を拡大しつつあります。こうした技術の進歩はすべて、狂犬病予防接種の安全性、有効性、利用しやすさを向上させ、発生時の迅速な対応を可能にし、予防ヘルスケアの範囲を広げることにつながっています。

ヒトと動物用医薬品の各分野で需要を牽引しているエンドユーザー区分は？

狂犬病ワクチン市場内の需要力学は、ヒトヘルスケア、獣医サービス、公衆衛生機関にまたがる多様な最終用途部門から強い影響を受けています。ヒトヘルスケアでは、病院、旅行診療所、農村部の保健センターが暴露後ワクチンの主要な消費者であり、公共部門の入札やWHOが認定したサプライヤーによって調達が増加しています。都市部の住民もまた、旅行や職業上のリスクの増加、教育普及活動により、曝露前ワクチン接種への関心が高まっています。一方、動物病院や動物保護施設では、家庭で飼われているペットや家畜、動物園の動物の予防接種にワクチンが使用され、並行市場が堅調に推移しています。特にペット産業はパンデミック後に大きく成長し、定期的な獣医師の診察とペットへのワクチン接種が同時に増加しています。農業および畜産部門、特に狂犬病が家畜や作業動物に感染する国では、予防ワクチン接種への投資も増加しています。OIE（世界動物保健機関）などの国際機関の支援を受けた政府の保健部門は、狂犬病の流行地域で、犬や野生動物の感染源を対象とした集団予防接種キャンペーンを展開するようになってきています。動物、人間、環境の健康が相互に関連していることを認識するワンヘルスの枠組みに狂犬病ワクチンを統合することで、多部門の協力と資金調達がさらに拡大しています。さらに、世界ヘルスや動物福祉に携わるNGOからの需要が、十分なサービスを受けていない地域でのワクチン配布に貢献しています。これらの多方面にわたる最終用途の動向は、人獣共通感染症との世界の闘いにおける医療上の必要性と戦略的手段の両方として、狂犬病ワクチンの重要性が高まっていることを裏付けています。

狂犬病ワクチン市場の成長は、技術進化、公衆衛生への取り組み、消費者行動の変化に関連するいくつかの要因によって牽引される

狂犬病ワクチン市場の成長は、技術の進歩、エンドユーザーのニーズの進化、ヘルスケア提供モデルの変化に関連するいくつかの要因によって牽引されています。主要な促進要因のひとつは、より優れた安全性プロファイルと簡便な投与レジメンを提供し、集団予防接種プログラムにより適している、最新の細胞培養ベースのワクチンへの広範な移行です。また、技術革新により、コールドチェーンに依存しないワクチンや、投与量を節約できる皮内投与が可能になり、遠隔地や十分なサービスを受けていない地域でのワクチン入手が大幅に改善されました。特にアジアやアフリカでは、政府主導による犬の集団予防接種キャンペーンが普及しつつあり、ヒト用・動物用狂犬病ワクチンの大規模調達が活発化しています。ペットの飼育率の上昇と動物医療サービスに対する需要が、民間セクターのワクチン売上をさらに押し上げています。WHOの「Zero by 30」戦略などの世界の公衆衛生イニシアチブの影響により、全国的な狂犬病対策プログラムに対する政治的・財政的支援が生み出され、ワクチンの配備が前年比で一貫して増加する原動力となっています。さらに、特に学校を中心とした教育プログラムやメディアへの働きかけを通じて、狂犬病の脅威に対する認識が高まり、非流行地域でも予防ワクチン接種に向けた消費者行動が変化しています。ヘルスケアシステムにおける調達戦略の進化により、一括購入、官民パートナーシップ、他のヘルスケアサービスとのワクチン一括納入が好まれ、流通が合理化され、費用効率が向上しています。最後に、狂犬病ワクチンが渡航勧告や雇用主が義務付ける健康診断に含まれるようになったことで、旅行者、駐在員、現場労働者の間で需要が拡大しています。このような多面的な要因が、世界の狂犬病ワクチン市場の持続的成長の原動力となっており、顧みられない熱帯病との闘いにおける重要なセグメントとして位置づけられています。

セグメント

製品タイプ（ニワトリ胚細胞狂犬病ワクチン、ヴェロ細胞狂犬病ワクチン、ヒト二倍体細胞ワクチン、その他の製品タイプ）;予防タイプ（曝露前予防、曝露後予防）;用途（ヒト、動物）;エンドユーザー（病院、動物病院、その他のエンドユーザー）

調査対象企業の例（注目の41社）

• AIM Vaccine Co., Ltd.
• AstraZeneca plc
• Bavarian Nordic A/S
• Berna Biotech Pharma GmbH
• Bharat Biotech International Ltd.
• Boehringer Ingelheim GmbH
• Cadila Pharmaceuticals Ltd.
• Chiron Behring Vaccines Pvt. Ltd.
• Elanco Animal Health Inc.
• GlaxoSmithKline plc（GSK）
• Indian Immunologicals Ltd.
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi S.A.
• Serum Institute of India Pvt. Ltd.
• VBI Vaccines Inc.
• Virbac S.A.
• Yisheng Biopharma Co., Ltd.
• Zoetis Inc.

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

無料アップデート弊社のお客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・産業団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストの厳選されたグループを含む1万4,949人のエコノミストを追跡しています。我々の16,491以上のレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Rabies Vaccine Market to Reach US$1.6 Billion by 2030

The global market for Rabies Vaccine estimated at US$1.3 Billion in the year 2024, is expected to reach US$1.6 Billion by 2030, growing at a CAGR of 3.8% over the analysis period 2024-2030. Chick Embryo Cells Rabies Vaccine, one of the segments analyzed in the report, is expected to record a 4.6% CAGR and reach US$708.0 Million by the end of the analysis period. Growth in the Vero Cell Rabies Vaccine segment is estimated at 3.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$347.7 Million While China is Forecast to Grow at 7.2% CAGR

The Rabies Vaccine market in the U.S. is estimated at US$347.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$324.8 Million by the year 2030 trailing a CAGR of 7.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.5% and 3.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.2% CAGR.

Global “Rabies Vaccine” Market - Key Trends & Drivers Summarized

Why Is the Rabies Vaccine Market Gaining Global Attention Amid Persistent Health Threats?

Rabies continues to be one of the most fatal yet entirely preventable diseases, claiming over 59,000 lives globally each year-primarily in Asia and Africa. Despite being 100% vaccine-preventable, under-reporting, limited access to healthcare, and lack of awareness have historically hindered adequate immunization. The global rabies vaccine market is gaining increased attention as governments, non-governmental organizations, and international health agencies-such as the WHO and GAVI-scale up efforts to eliminate human deaths from dog-mediated rabies by 2030. Demand is growing for both pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP), especially in rural and high-risk populations where dog bites are most common. Rising awareness campaigns and mandatory dog vaccination drives are improving coverage rates. Moreover, the resurgence of global travel and tourism has added another layer of demand, with travelers requiring PrEP before visiting rabies-endemic regions. Educational institutions, animal welfare centers, and veterinary clinics are increasingly stocking rabies vaccines, recognizing their role in community protection. On a broader scale, public health funding aimed at neglected tropical diseases is being channeled toward national rabies control programs, driving consistent procurement of both human and veterinary rabies vaccines. The increase in pet adoption and heightened focus on zoonotic disease prevention post-COVID-19 have also elevated the profile of rabies vaccination as a public health priority, setting the stage for long-term market expansion.

How Are Innovations in Vaccine Technology Transforming Rabies Immunization Programs?

The rabies vaccine landscape is witnessing a technological transformation as manufacturers shift from outdated nerve tissue vaccines to more advanced cell culture-based vaccines such as purified chick embryo cell vaccine (PCECV) and human diploid cell vaccine (HDCV). These newer vaccines offer improved immunogenicity, fewer adverse reactions, and require fewer doses, making them more compliant with modern immunization schedules. Research is also underway on monoclonal antibody-based biologics that could serve as faster-acting alternatives or adjuncts to traditional rabies immunoglobulins in post-exposure protocols. Additionally, thermostable vaccine formulations are emerging to address the challenge of cold chain logistics in remote and low-resource settings. Needle-free delivery methods, such as intradermal administration and micro-needle patches, are being trialed to improve ease of use, reduce dosage requirements, and enhance patient compliance. Digital health innovations-such as mobile apps and blockchain for vaccine tracking and verification-are streamlining immunization records and improving monitoring in decentralized vaccination campaigns. Leading pharmaceutical firms are also investing in adjuvant technologies to enhance long-lasting immunity with fewer injections. Moreover, innovations in veterinary rabies vaccines, such as oral bait vaccines for wild animals, are expanding control strategies beyond domestic pets. All these technological advances are converging to enhance the safety, efficacy, and accessibility of rabies immunization, enabling faster response times in outbreak situations and broadening the scope of preventive healthcare.

Which End-Use Segments Are Driving Demand Across Human and Veterinary Health Sectors?

The demand dynamics within the rabies vaccine market are being strongly influenced by diverse end-use sectors spanning human healthcare, veterinary services, and public health agencies. In human healthcare, hospitals, travel clinics, and rural health centers are leading consumers of post-exposure vaccines, with increasing procurement supported by public-sector tenders and WHO-prequalified suppliers. Urban populations are also showing increased interest in pre-exposure vaccination due to heightened travel, occupational risks, and educational outreach. Meanwhile, veterinary clinics and animal shelters represent a robust parallel market, where vaccines are used to immunize domestic pets, livestock, and zoo animals. The pet industry, in particular, has grown significantly post-pandemic, with a concurrent rise in routine veterinary visits and pet vaccinations. Agricultural and livestock sectors, particularly in countries where rabies affects cattle and working animals, are also investing more in prophylactic vaccination. Government health departments, supported by international organizations such as OIE (World Organisation for Animal Health), are increasingly deploying mass vaccination campaigns in endemic regions, targeting dogs and wildlife reservoirs. The integration of rabies vaccines in One Health frameworks-recognizing the interconnectedness of animal, human, and environmental health-is further expanding multi-sectoral collaboration and funding. Additionally, demand from NGOs involved in global health and animal welfare is contributing to vaccine distribution in underserved areas. Together, these multi-pronged end-use trends underscore the rising importance of rabies vaccines as both a medical necessity and a strategic tool in the global fight against zoonotic diseases.

The Growth in the Rabies Vaccine Market Is Driven by Several Factors Related to Technological Evolution, Public Health Initiatives, and Shifting Consumer Behavior

The growth in the rabies vaccine market is driven by several factors related to technological advancements, evolving end-user needs, and changes in healthcare delivery models. One key driver is the widespread transition to modern, cell culture-based vaccines that offer better safety profiles and simplified dosing regimens-making them more suitable for mass immunization programs. Technological innovation has also enabled cold chain-independent vaccines and dose-sparing intradermal delivery, significantly improving vaccine accessibility in remote and underserved regions. The increasing prevalence of government-led mass dog vaccination campaigns-especially in Asia and Africa-is stimulating large-scale procurement of both human and veterinary rabies vaccines. Rising pet ownership and demand for animal health services are further boosting vaccine sales in the private sector. The influence of global public health initiatives, such as the WHO’s “Zero by 30” strategy, is generating political and financial support for nationwide rabies control programs, driving consistent year-on-year growth in vaccine deployment. Additionally, greater awareness of the rabies threat, especially through school-based education programs and media outreach, is shifting consumer behavior toward preventive vaccination even in non-endemic regions. Evolving procurement strategies in the healthcare system-favoring bulk purchasing, public-private partnerships, and bundled delivery of vaccines with other healthcare services-are streamlining distribution and improving cost-efficiency. Lastly, the inclusion of rabies vaccines in travel advisories and employer-mandated health screenings is expanding demand among travelers, expatriates, and field workers. Together, these multidimensional factors are powering sustained growth in the global rabies vaccine market, positioning it as a critical segment in the fight against neglected tropical diseases.

SCOPE OF STUDY:

The report analyzes the Rabies Vaccine market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine, Other Product Types); Prophylaxis Type (Pre-Exposure Prophylaxis, Post-Exposure Prophylaxis); Application (Human, Animal); End-User (Hospitals, Veterinary Clinics, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

• AIM Vaccine Co., Ltd.
• AstraZeneca plc
• Bavarian Nordic A/S
• Berna Biotech Pharma GmbH
• Bharat Biotech International Ltd.
• Boehringer Ingelheim GmbH
• Cadila Pharmaceuticals Ltd.
• Chiron Behring Vaccines Pvt. Ltd.
• Elanco Animal Health Inc.
• GlaxoSmithKline plc (GSK)
• Indian Immunologicals Ltd.
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi S.A.
• Serum Institute of India Pvt. Ltd.
• VBI Vaccines Inc.
• Virbac S.A.
• Yisheng Biopharma Co., Ltd.
• Zoetis Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • Rabies Vaccine - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Global Incidence of Rabies in Developing Regions Drives Demand for Preventive Vaccination
  • Growing Government-Led Mass Immunization Programs Strengthen Public Sector Procurement
  • Technological Advancements in Cell Culture-Based Vaccines Improve Safety and Efficacy Profiles
  • WHO Initiatives for Zero Human Rabies Deaths by 2030 Spur International Funding and Adoption
  • Expansion of Veterinary Rabies Vaccination Programs Boosts Animal Health Market Penetration
  • Cold Chain Infrastructure Development Improves Vaccine Reach in Remote Areas
  • Increased Partnerships Between Global Health Agencies and Manufacturers Accelerate Access
  • Growing Awareness of Pre-Exposure Prophylaxis Among Travelers Expands Target Market
  • Private Sector Entry into Animal and Human Vaccine Manufacturing Drives Competitive Landscape
  • Emergence of Single-Dose Regimens Enhances Convenience and Compliance in Endemic Regions
  • R&D in Recombinant Rabies Vaccines Opens New Avenues for Innovation
  • Government Regulation of Pet Ownership and Stray Animal Control Encourages Domestic Vaccine Uptake
  • Public Health Campaigns Highlighting Rabies Risks Strengthen Surveillance and Reporting
  • Investment in Veterinary Clinics and Pet Care Ecosystems Supports Preventive Inoculation
  • Regional Manufacturing Capabilities Improve Affordability and Supply Chain Stability
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Rabies Vaccine Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Rabies Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Rabies Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Rabies Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Chick Embryo Cells Rabies Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Chick Embryo Cells Rabies Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Chick Embryo Cells Rabies Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Vero Cell Rabies Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Vero Cell Rabies Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Vero Cell Rabies Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Human Diploid Cell Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Human Diploid Cell Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Human Diploid Cell Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Other Product Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Veterinary Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Veterinary Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Veterinary Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Pre-Exposure Prophylaxis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Pre-Exposure Prophylaxis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Pre-Exposure Prophylaxis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Post-Exposure Prophylaxis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Post-Exposure Prophylaxis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Post-Exposure Prophylaxis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Human by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Human by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Human by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Animal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Animal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Animal by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Rabies Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 38: USA Recent Past, Current & Future Analysis for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 40: USA 15-Year Perspective for Rabies Vaccine by Product Type - Percentage Breakdown of Value Sales for Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 41: USA Recent Past, Current & Future Analysis for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 43: USA 15-Year Perspective for Rabies Vaccine by End-user - Percentage Breakdown of Value Sales for Veterinary Clinics, Other End-Users and Hospitals for the Years 2015, 2025 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 46: USA 15-Year Perspective for Rabies Vaccine by Prophylaxis Type - Percentage Breakdown of Value Sales for Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis for the Years 2015, 2025 & 2030
  • TABLE 47: USA Recent Past, Current & Future Analysis for Rabies Vaccine by Application - Human and Animal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 48: USA Historic Review for Rabies Vaccine by Application - Human and Animal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 49: USA 15-Year Perspective for Rabies Vaccine by Application - Percentage Breakdown of Value Sales for Human and Animal for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 52: Canada 15-Year Perspective for Rabies Vaccine by Product Type - Percentage Breakdown of Value Sales for Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 55: Canada 15-Year Perspective for Rabies Vaccine by End-user - Percentage Breakdown of Value Sales for Veterinary Clinics, Other End-Users and Hospitals for the Years 2015, 2025 & 2030
  • TABLE 56: Canada Recent Past, Current & Future Analysis for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Canada Historic Review for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 58: Canada 15-Year Perspective for Rabies Vaccine by Prophylaxis Type - Percentage Breakdown of Value Sales for Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis for the Years 2015, 2025 & 2030
  • TABLE 59: Canada Recent Past, Current & Future Analysis for Rabies Vaccine by Application - Human and Animal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Canada Historic Review for Rabies Vaccine by Application - Human and Animal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 61: Canada 15-Year Perspective for Rabies Vaccine by Application - Percentage Breakdown of Value Sales for Human and Animal for the Years 2015, 2025 & 2030
• JAPAN
  • Rabies Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 64: Japan 15-Year Perspective for Rabies Vaccine by Product Type - Percentage Breakdown of Value Sales for Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 65: Japan Recent Past, Current & Future Analysis for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Japan Historic Review for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 67: Japan 15-Year Perspective for Rabies Vaccine by End-user - Percentage Breakdown of Value Sales for Veterinary Clinics, Other End-Users and Hospitals for the Years 2015, 2025 & 2030
  • TABLE 68: Japan Recent Past, Current & Future Analysis for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Japan Historic Review for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 70: Japan 15-Year Perspective for Rabies Vaccine by Prophylaxis Type - Percentage Breakdown of Value Sales for Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis for the Years 2015, 2025 & 2030
  • TABLE 71: Japan Recent Past, Current & Future Analysis for Rabies Vaccine by Application - Human and Animal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Japan Historic Review for Rabies Vaccine by Application - Human and Animal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 73: Japan 15-Year Perspective for Rabies Vaccine by Application - Percentage Breakdown of Value Sales for Human and Animal for the Years 2015, 2025 & 2030
• CHINA
  • Rabies Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 74: China Recent Past, Current & Future Analysis for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 75: China Historic Review for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 76: China 15-Year Perspective for Rabies Vaccine by Product Type - Percentage Breakdown of Value Sales for Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 77: China Recent Past, Current & Future Analysis for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: China Historic Review for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 79: China 15-Year Perspective for Rabies Vaccine by End-user - Percentage Breakdown of Value Sales for Veterinary Clinics, Other End-Users and Hospitals for the Years 2015, 2025 & 2030
  • TABLE 80: China Recent Past, Current & Future Analysis for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: China Historic Review for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 82: China 15-Year Perspective for Rabies Vaccine by Prophylaxis Type - Percentage Breakdown of Value Sales for Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis for the Years 2015, 2025 & 2030
  • TABLE 83: China Recent Past, Current & Future Analysis for Rabies Vaccine by Application - Human and Animal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: China Historic Review for Rabies Vaccine by Application - Human and Animal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 85: China 15-Year Perspective for Rabies Vaccine by Application - Percentage Breakdown of Value Sales for Human and Animal for the Years 2015, 2025 & 2030
• EUROPE
  • Rabies Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 86: Europe Recent Past, Current & Future Analysis for Rabies Vaccine by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 87: Europe Historic Review for Rabies Vaccine by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 88: Europe 15-Year Perspective for Rabies Vaccine by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 89: Europe Recent Past, Current & Future Analysis for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Europe Historic Review for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 91: Europe 15-Year Perspective for Rabies Vaccine by Product Type - Percentage Breakdown of Value Sales for Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 92: Europe Recent Past, Current & Future Analysis for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Europe Historic Review for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 94: Europe 15-Year Perspective for Rabies Vaccine by End-user - Percentage Breakdown of Value Sales for Veterinary Clinics, Other End-Users and Hospitals for the Years 2015, 2025 & 2030
  • TABLE 95: Europe Recent Past, Current & Future Analysis for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Europe Historic Review for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 97: Europe 15-Year Perspective for Rabies Vaccine by Prophylaxis Type - Percentage Breakdown of Value Sales for Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis for the Years 2015, 2025 & 2030
  • TABLE 98: Europe Recent Past, Current & Future Analysis for Rabies Vaccine by Application - Human and Animal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Europe Historic Review for Rabies Vaccine by Application - Human and Animal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 100: Europe 15-Year Perspective for Rabies Vaccine by Application - Percentage Breakdown of Value Sales for Human and Animal for the Years 2015, 2025 & 2030
• FRANCE
  • Rabies Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 101: France Recent Past, Current & Future Analysis for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: France Historic Review for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 103: France 15-Year Perspective for Rabies Vaccine by Product Type - Percentage Breakdown of Value Sales for Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 104: France Recent Past, Current & Future Analysis for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: France Historic Review for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 106: France 15-Year Perspective for Rabies Vaccine by End-user - Percentage Breakdown of Value Sales for Veterinary Clinics, Other End-Users and Hospitals for the Years 2015, 2025 & 2030
  • TABLE 107: France Recent Past, Current & Future Analysis for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 108: France Historic Review for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 109: France 15-Year Perspective for Rabies Vaccine by Prophylaxis Type - Percentage Breakdown of Value Sales for Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis for the Years 2015, 2025 & 2030
  • TABLE 110: France Recent Past, Current & Future Analysis for Rabies Vaccine by Application - Human and Animal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: France Historic Review for Rabies Vaccine by Application - Human and Animal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 112: France 15-Year Perspective for Rabies Vaccine by Application - Percentage Breakdown of Value Sales for Human and Animal for the Years 2015, 2025 & 2030
• GERMANY
  • Rabies Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 113: Germany Recent Past, Current & Future Analysis for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Germany Historic Review for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 115: Germany 15-Year Perspective for Rabies Vaccine by Product Type - Percentage Breakdown of Value Sales for Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 116: Germany Recent Past, Current & Future Analysis for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Germany Historic Review for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 118: Germany 15-Year Perspective for Rabies Vaccine by End-user - Percentage Breakdown of Value Sales for Veterinary Clinics, Other End-Users and Hospitals for the Years 2015, 2025 & 2030
  • TABLE 119: Germany Recent Past, Current & Future Analysis for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Germany Historic Review for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 121: Germany 15-Year Perspective for Rabies Vaccine by Prophylaxis Type - Percentage Breakdown of Value Sales for Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis for the Years 2015, 2025 & 2030
  • TABLE 122: Germany Recent Past, Current & Future Analysis for Rabies Vaccine by Application - Human and Animal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Germany Historic Review for Rabies Vaccine by Application - Human and Animal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 124: Germany 15-Year Perspective for Rabies Vaccine by Application - Percentage Breakdown of Value Sales for Human and Animal for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 125: Italy Recent Past, Current & Future Analysis for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Italy Historic Review for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 127: Italy 15-Year Perspective for Rabies Vaccine by Product Type - Percentage Breakdown of Value Sales for Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 128: Italy Recent Past, Current & Future Analysis for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Italy Historic Review for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 130: Italy 15-Year Perspective for Rabies Vaccine by End-user - Percentage Breakdown of Value Sales for Veterinary Clinics, Other End-Users and Hospitals for the Years 2015, 2025 & 2030
  • TABLE 131: Italy Recent Past, Current & Future Analysis for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Italy Historic Review for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 133: Italy 15-Year Perspective for Rabies Vaccine by Prophylaxis Type - Percentage Breakdown of Value Sales for Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis for the Years 2015, 2025 & 2030
  • TABLE 134: Italy Recent Past, Current & Future Analysis for Rabies Vaccine by Application - Human and Animal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Italy Historic Review for Rabies Vaccine by Application - Human and Animal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 136: Italy 15-Year Perspective for Rabies Vaccine by Application - Percentage Breakdown of Value Sales for Human and Animal for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Rabies Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 137: UK Recent Past, Current & Future Analysis for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 138: UK Historic Review for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 139: UK 15-Year Perspective for Rabies Vaccine by Product Type - Percentage Breakdown of Value Sales for Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 140: UK Recent Past, Current & Future Analysis for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 141: UK Historic Review for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 142: UK 15-Year Perspective for Rabies Vaccine by End-user - Percentage Breakdown of Value Sales for Veterinary Clinics, Other End-Users and Hospitals for the Years 2015, 2025 & 2030
  • TABLE 143: UK Recent Past, Current & Future Analysis for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 144: UK Historic Review for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 145: UK 15-Year Perspective for Rabies Vaccine by Prophylaxis Type - Percentage Breakdown of Value Sales for Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis for the Years 2015, 2025 & 2030
  • TABLE 146: UK Recent Past, Current & Future Analysis for Rabies Vaccine by Application - Human and Animal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 147: UK Historic Review for Rabies Vaccine by Application - Human and Animal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 148: UK 15-Year Perspective for Rabies Vaccine by Application - Percentage Breakdown of Value Sales for Human and Animal for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 149: Spain Recent Past, Current & Future Analysis for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Spain Historic Review for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 151: Spain 15-Year Perspective for Rabies Vaccine by Product Type - Percentage Breakdown of Value Sales for Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 152: Spain Recent Past, Current & Future Analysis for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Spain Historic Review for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 154: Spain 15-Year Perspective for Rabies Vaccine by End-user - Percentage Breakdown of Value Sales for Veterinary Clinics, Other End-Users and Hospitals for the Years 2015, 2025 & 2030
  • TABLE 155: Spain Recent Past, Current & Future Analysis for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Spain Historic Review for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 157: Spain 15-Year Perspective for Rabies Vaccine by Prophylaxis Type - Percentage Breakdown of Value Sales for Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis for the Years 2015, 2025 & 2030
  • TABLE 158: Spain Recent Past, Current & Future Analysis for Rabies Vaccine by Application - Human and Animal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Spain Historic Review for Rabies Vaccine by Application - Human and Animal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 160: Spain 15-Year Perspective for Rabies Vaccine by Application - Percentage Breakdown of Value Sales for Human and Animal for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 161: Russia Recent Past, Current & Future Analysis for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Russia Historic Review for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 163: Russia 15-Year Perspective for Rabies Vaccine by Product Type - Percentage Breakdown of Value Sales for Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 164: Russia Recent Past, Current & Future Analysis for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Russia Historic Review for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 166: Russia 15-Year Perspective for Rabies Vaccine by End-user - Percentage Breakdown of Value Sales for Veterinary Clinics, Other End-Users and Hospitals for the Years 2015, 2025 & 2030
  • TABLE 167: Russia Recent Past, Current & Future Analysis for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Russia Historic Review for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 169: Russia 15-Year Perspective for Rabies Vaccine by Prophylaxis Type - Percentage Breakdown of Value Sales for Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis for the Years 2015, 2025 & 2030
  • TABLE 170: Russia Recent Past, Current & Future Analysis for Rabies Vaccine by Application - Human and Animal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Russia Historic Review for Rabies Vaccine by Application - Human and Animal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 172: Russia 15-Year Perspective for Rabies Vaccine by Application - Percentage Breakdown of Value Sales for Human and Animal for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 173: Rest of Europe Recent Past, Current & Future Analysis for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Rest of Europe Historic Review for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 175: Rest of Europe 15-Year Perspective for Rabies Vaccine by Product Type - Percentage Breakdown of Value Sales for Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 176: Rest of Europe Recent Past, Current & Future Analysis for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Rest of Europe Historic Review for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 178: Rest of Europe 15-Year Perspective for Rabies Vaccine by End-user - Percentage Breakdown of Value Sales for Veterinary Clinics, Other End-Users and Hospitals for the Years 2015, 2025 & 2030
  • TABLE 179: Rest of Europe Recent Past, Current & Future Analysis for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Rest of Europe Historic Review for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 181: Rest of Europe 15-Year Perspective for Rabies Vaccine by Prophylaxis Type - Percentage Breakdown of Value Sales for Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis for the Years 2015, 2025 & 2030
  • TABLE 182: Rest of Europe Recent Past, Current & Future Analysis for Rabies Vaccine by Application - Human and Animal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Rest of Europe Historic Review for Rabies Vaccine by Application - Human and Animal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 184: Rest of Europe 15-Year Perspective for Rabies Vaccine by Application - Percentage Breakdown of Value Sales for Human and Animal for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Rabies Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 185: Asia-Pacific Recent Past, Current & Future Analysis for Rabies Vaccine by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 186: Asia-Pacific Historic Review for Rabies Vaccine by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 187: Asia-Pacific 15-Year Perspective for Rabies Vaccine by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 188: Asia-Pacific Recent Past, Current & Future Analysis for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Asia-Pacific Historic Review for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 190: Asia-Pacific 15-Year Perspective for Rabies Vaccine by Product Type - Percentage Breakdown of Value Sales for Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 191: Asia-Pacific Recent Past, Current & Future Analysis for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Asia-Pacific Historic Review for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 193: Asia-Pacific 15-Year Perspective for Rabies Vaccine by End-user - Percentage Breakdown of Value Sales for Veterinary Clinics, Other End-Users and Hospitals for the Years 2015, 2025 & 2030
  • TABLE 194: Asia-Pacific Recent Past, Current & Future Analysis for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Asia-Pacific Historic Review for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 196: Asia-Pacific 15-Year Perspective for Rabies Vaccine by Prophylaxis Type - Percentage Breakdown of Value Sales for Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis for the Years 2015, 2025 & 2030
  • TABLE 197: Asia-Pacific Recent Past, Current & Future Analysis for Rabies Vaccine by Application - Human and Animal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Asia-Pacific Historic Review for Rabies Vaccine by Application - Human and Animal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 199: Asia-Pacific 15-Year Perspective for Rabies Vaccine by Application - Percentage Breakdown of Value Sales for Human and Animal for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Rabies Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 200: Australia Recent Past, Current & Future Analysis for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Australia Historic Review for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 202: Australia 15-Year Perspective for Rabies Vaccine by Product Type - Percentage Breakdown of Value Sales for Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 203: Australia Recent Past, Current & Future Analysis for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Australia Historic Review for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 205: Australia 15-Year Perspective for Rabies Vaccine by End-user - Percentage Breakdown of Value Sales for Veterinary Clinics, Other End-Users and Hospitals for the Years 2015, 2025 & 2030
  • TABLE 206: Australia Recent Past, Current & Future Analysis for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Australia Historic Review for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 208: Australia 15-Year Perspective for Rabies Vaccine by Prophylaxis Type - Percentage Breakdown of Value Sales for Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis for the Years 2015, 2025 & 2030
  • TABLE 209: Australia Recent Past, Current & Future Analysis for Rabies Vaccine by Application - Human and Animal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Australia Historic Review for Rabies Vaccine by Application - Human and Animal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 211: Australia 15-Year Perspective for Rabies Vaccine by Application - Percentage Breakdown of Value Sales for Human and Animal for the Years 2015, 2025 & 2030
• INDIA
  • Rabies Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 212: India Recent Past, Current & Future Analysis for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 213: India Historic Review for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 214: India 15-Year Perspective for Rabies Vaccine by Product Type - Percentage Breakdown of Value Sales for Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 215: India Recent Past, Current & Future Analysis for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 216: India Historic Review for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 217: India 15-Year Perspective for Rabies Vaccine by End-user - Percentage Breakdown of Value Sales for Veterinary Clinics, Other End-Users and Hospitals for the Years 2015, 2025 & 2030
  • TABLE 218: India Recent Past, Current & Future Analysis for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 219: India Historic Review for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 220: India 15-Year Perspective for Rabies Vaccine by Prophylaxis Type - Percentage Breakdown of Value Sales for Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis for the Years 2015, 2025 & 2030
  • TABLE 221: India Recent Past, Current & Future Analysis for Rabies Vaccine by Application - Human and Animal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 222: India Historic Review for Rabies Vaccine by Application - Human and Animal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 223: India 15-Year Perspective for Rabies Vaccine by Application - Percentage Breakdown of Value Sales for Human and Animal for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 224: South Korea Recent Past, Current & Future Analysis for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 225: South Korea Historic Review for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 226: South Korea 15-Year Perspective for Rabies Vaccine by Product Type - Percentage Breakdown of Value Sales for Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 227: South Korea Recent Past, Current & Future Analysis for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 228: South Korea Historic Review for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 229: South Korea 15-Year Perspective for Rabies Vaccine by End-user - Percentage Breakdown of Value Sales for Veterinary Clinics, Other End-Users and Hospitals for the Years 2015, 2025 & 2030
  • TABLE 230: South Korea Recent Past, Current & Future Analysis for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 231: South Korea Historic Review for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 232: South Korea 15-Year Perspective for Rabies Vaccine by Prophylaxis Type - Percentage Breakdown of Value Sales for Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis for the Years 2015, 2025 & 2030
  • TABLE 233: South Korea Recent Past, Current & Future Analysis for Rabies Vaccine by Application - Human and Animal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 234: South Korea Historic Review for Rabies Vaccine by Application - Human and Animal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 235: South Korea 15-Year Perspective for Rabies Vaccine by Application - Percentage Breakdown of Value Sales for Human and Animal for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 236: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Asia-Pacific Historic Review for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 238: Rest of Asia-Pacific 15-Year Perspective for Rabies Vaccine by Product Type - Percentage Breakdown of Value Sales for Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 239: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Asia-Pacific Historic Review for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Asia-Pacific 15-Year Perspective for Rabies Vaccine by End-user - Percentage Breakdown of Value Sales for Veterinary Clinics, Other End-Users and Hospitals for the Years 2015, 2025 & 2030
  • TABLE 242: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Asia-Pacific Historic Review for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 244: Rest of Asia-Pacific 15-Year Perspective for Rabies Vaccine by Prophylaxis Type - Percentage Breakdown of Value Sales for Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis for the Years 2015, 2025 & 2030
  • TABLE 245: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Rabies Vaccine by Application - Human and Animal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Rest of Asia-Pacific Historic Review for Rabies Vaccine by Application - Human and Animal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 247: Rest of Asia-Pacific 15-Year Perspective for Rabies Vaccine by Application - Percentage Breakdown of Value Sales for Human and Animal for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Rabies Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 248: Latin America Recent Past, Current & Future Analysis for Rabies Vaccine by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 249: Latin America Historic Review for Rabies Vaccine by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 250: Latin America 15-Year Perspective for Rabies Vaccine by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 251: Latin America Recent Past, Current & Future Analysis for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Latin America Historic Review for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 253: Latin America 15-Year Perspective for Rabies Vaccine by Product Type - Percentage Breakdown of Value Sales for Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 254: Latin America Recent Past, Current & Future Analysis for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Latin America Historic Review for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 256: Latin America 15-Year Perspective for Rabies Vaccine by End-user - Percentage Breakdown of Value Sales for Veterinary Clinics, Other End-Users and Hospitals for the Years 2015, 2025 & 2030
  • TABLE 257: Latin America Recent Past, Current & Future Analysis for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Latin America Historic Review for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 259: Latin America 15-Year Perspective for Rabies Vaccine by Prophylaxis Type - Percentage Breakdown of Value Sales for Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis for the Years 2015, 2025 & 2030
  • TABLE 260: Latin America Recent Past, Current & Future Analysis for Rabies Vaccine by Application - Human and Animal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Latin America Historic Review for Rabies Vaccine by Application - Human and Animal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 262: Latin America 15-Year Perspective for Rabies Vaccine by Application - Percentage Breakdown of Value Sales for Human and Animal for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 263: Argentina Recent Past, Current & Future Analysis for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Argentina Historic Review for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 265: Argentina 15-Year Perspective for Rabies Vaccine by Product Type - Percentage Breakdown of Value Sales for Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 266: Argentina Recent Past, Current & Future Analysis for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Argentina Historic Review for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 268: Argentina 15-Year Perspective for Rabies Vaccine by End-user - Percentage Breakdown of Value Sales for Veterinary Clinics, Other End-Users and Hospitals for the Years 2015, 2025 & 2030
  • TABLE 269: Argentina Recent Past, Current & Future Analysis for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Argentina Historic Review for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 271: Argentina 15-Year Perspective for Rabies Vaccine by Prophylaxis Type - Percentage Breakdown of Value Sales for Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis for the Years 2015, 2025 & 2030
  • TABLE 272: Argentina Recent Past, Current & Future Analysis for Rabies Vaccine by Application - Human and Animal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Argentina Historic Review for Rabies Vaccine by Application - Human and Animal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 274: Argentina 15-Year Perspective for Rabies Vaccine by Application - Percentage Breakdown of Value Sales for Human and Animal for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 275: Brazil Recent Past, Current & Future Analysis for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Brazil Historic Review for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 277: Brazil 15-Year Perspective for Rabies Vaccine by Product Type - Percentage Breakdown of Value Sales for Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 278: Brazil Recent Past, Current & Future Analysis for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Brazil Historic Review for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 280: Brazil 15-Year Perspective for Rabies Vaccine by End-user - Percentage Breakdown of Value Sales for Veterinary Clinics, Other End-Users and Hospitals for the Years 2015, 2025 & 2030
  • TABLE 281: Brazil Recent Past, Current & Future Analysis for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Brazil Historic Review for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 283: Brazil 15-Year Perspective for Rabies Vaccine by Prophylaxis Type - Percentage Breakdown of Value Sales for Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis for the Years 2015, 2025 & 2030
  • TABLE 284: Brazil Recent Past, Current & Future Analysis for Rabies Vaccine by Application - Human and Animal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Brazil Historic Review for Rabies Vaccine by Application - Human and Animal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 286: Brazil 15-Year Perspective for Rabies Vaccine by Application - Percentage Breakdown of Value Sales for Human and Animal for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 287: Mexico Recent Past, Current & Future Analysis for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Mexico Historic Review for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 289: Mexico 15-Year Perspective for Rabies Vaccine by Product Type - Percentage Breakdown of Value Sales for Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 290: Mexico Recent Past, Current & Future Analysis for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Mexico Historic Review for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 292: Mexico 15-Year Perspective for Rabies Vaccine by End-user - Percentage Breakdown of Value Sales for Veterinary Clinics, Other End-Users and Hospitals for the Years 2015, 2025 & 2030
  • TABLE 293: Mexico Recent Past, Current & Future Analysis for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Mexico Historic Review for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 295: Mexico 15-Year Perspective for Rabies Vaccine by Prophylaxis Type - Percentage Breakdown of Value Sales for Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis for the Years 2015, 2025 & 2030
  • TABLE 296: Mexico Recent Past, Current & Future Analysis for Rabies Vaccine by Application - Human and Animal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Mexico Historic Review for Rabies Vaccine by Application - Human and Animal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 298: Mexico 15-Year Perspective for Rabies Vaccine by Application - Percentage Breakdown of Value Sales for Human and Animal for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 299: Rest of Latin America Recent Past, Current & Future Analysis for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Rest of Latin America Historic Review for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 301: Rest of Latin America 15-Year Perspective for Rabies Vaccine by Product Type - Percentage Breakdown of Value Sales for Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 302: Rest of Latin America Recent Past, Current & Future Analysis for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Rest of Latin America Historic Review for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 304: Rest of Latin America 15-Year Perspective for Rabies Vaccine by End-user - Percentage Breakdown of Value Sales for Veterinary Clinics, Other End-Users and Hospitals for the Years 2015, 2025 & 2030
  • TABLE 305: Rest of Latin America Recent Past, Current & Future Analysis for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Rest of Latin America Historic Review for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 307: Rest of Latin America 15-Year Perspective for Rabies Vaccine by Prophylaxis Type - Percentage Breakdown of Value Sales for Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis for the Years 2015, 2025 & 2030
  • TABLE 308: Rest of Latin America Recent Past, Current & Future Analysis for Rabies Vaccine by Application - Human and Animal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Rest of Latin America Historic Review for Rabies Vaccine by Application - Human and Animal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 310: Rest of Latin America 15-Year Perspective for Rabies Vaccine by Application - Percentage Breakdown of Value Sales for Human and Animal for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Rabies Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 311: Middle East Recent Past, Current & Future Analysis for Rabies Vaccine by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 312: Middle East Historic Review for Rabies Vaccine by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 313: Middle East 15-Year Perspective for Rabies Vaccine by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 314: Middle East Recent Past, Current & Future Analysis for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Middle East Historic Review for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 316: Middle East 15-Year Perspective for Rabies Vaccine by Product Type - Percentage Breakdown of Value Sales for Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 317: Middle East Recent Past, Current & Future Analysis for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Middle East Historic Review for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 319: Middle East 15-Year Perspective for Rabies Vaccine by End-user - Percentage Breakdown of Value Sales for Veterinary Clinics, Other End-Users and Hospitals for the Years 2015, 2025 & 2030
  • TABLE 320: Middle East Recent Past, Current & Future Analysis for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Middle East Historic Review for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 322: Middle East 15-Year Perspective for Rabies Vaccine by Prophylaxis Type - Percentage Breakdown of Value Sales for Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis for the Years 2015, 2025 & 2030
  • TABLE 323: Middle East Recent Past, Current & Future Analysis for Rabies Vaccine by Application - Human and Animal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 324: Middle East Historic Review for Rabies Vaccine by Application - Human and Animal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 325: Middle East 15-Year Perspective for Rabies Vaccine by Application - Percentage Breakdown of Value Sales for Human and Animal for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 326: Iran Recent Past, Current & Future Analysis for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 327: Iran Historic Review for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 328: Iran 15-Year Perspective for Rabies Vaccine by Product Type - Percentage Breakdown of Value Sales for Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 329: Iran Recent Past, Current & Future Analysis for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 330: Iran Historic Review for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 331: Iran 15-Year Perspective for Rabies Vaccine by End-user - Percentage Breakdown of Value Sales for Veterinary Clinics, Other End-Users and Hospitals for the Years 2015, 2025 & 2030
  • TABLE 332: Iran Recent Past, Current & Future Analysis for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 333: Iran Historic Review for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 334: Iran 15-Year Perspective for Rabies Vaccine by Prophylaxis Type - Percentage Breakdown of Value Sales for Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis for the Years 2015, 2025 & 2030
  • TABLE 335: Iran Recent Past, Current & Future Analysis for Rabies Vaccine by Application - Human and Animal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 336: Iran Historic Review for Rabies Vaccine by Application - Human and Animal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 337: Iran 15-Year Perspective for Rabies Vaccine by Application - Percentage Breakdown of Value Sales for Human and Animal for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 338: Israel Recent Past, Current & Future Analysis for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 339: Israel Historic Review for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 340: Israel 15-Year Perspective for Rabies Vaccine by Product Type - Percentage Breakdown of Value Sales for Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 341: Israel Recent Past, Current & Future Analysis for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 342: Israel Historic Review for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 343: Israel 15-Year Perspective for Rabies Vaccine by End-user - Percentage Breakdown of Value Sales for Veterinary Clinics, Other End-Users and Hospitals for the Years 2015, 2025 & 2030
  • TABLE 344: Israel Recent Past, Current & Future Analysis for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 345: Israel Historic Review for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 346: Israel 15-Year Perspective for Rabies Vaccine by Prophylaxis Type - Percentage Breakdown of Value Sales for Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis for the Years 2015, 2025 & 2030
  • TABLE 347: Israel Recent Past, Current & Future Analysis for Rabies Vaccine by Application - Human and Animal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 348: Israel Historic Review for Rabies Vaccine by Application - Human and Animal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 349: Israel 15-Year Perspective for Rabies Vaccine by Application - Percentage Breakdown of Value Sales for Human and Animal for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 350: Saudi Arabia Recent Past, Current & Future Analysis for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 351: Saudi Arabia Historic Review for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 352: Saudi Arabia 15-Year Perspective for Rabies Vaccine by Product Type - Percentage Breakdown of Value Sales for Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 353: Saudi Arabia Recent Past, Current & Future Analysis for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 354: Saudi Arabia Historic Review for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 355: Saudi Arabia 15-Year Perspective for Rabies Vaccine by End-user - Percentage Breakdown of Value Sales for Veterinary Clinics, Other End-Users and Hospitals for the Years 2015, 2025 & 2030
  • TABLE 356: Saudi Arabia Recent Past, Current & Future Analysis for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 357: Saudi Arabia Historic Review for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 358: Saudi Arabia 15-Year Perspective for Rabies Vaccine by Prophylaxis Type - Percentage Breakdown of Value Sales for Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis for the Years 2015, 2025 & 2030
  • TABLE 359: Saudi Arabia Recent Past, Current & Future Analysis for Rabies Vaccine by Application - Human and Animal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 360: Saudi Arabia Historic Review for Rabies Vaccine by Application - Human and Animal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 361: Saudi Arabia 15-Year Perspective for Rabies Vaccine by Application - Percentage Breakdown of Value Sales for Human and Animal for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 362: UAE Recent Past, Current & Future Analysis for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 363: UAE Historic Review for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 364: UAE 15-Year Perspective for Rabies Vaccine by Product Type - Percentage Breakdown of Value Sales for Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 365: UAE Recent Past, Current & Future Analysis for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 366: UAE Historic Review for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 367: UAE 15-Year Perspective for Rabies Vaccine by End-user - Percentage Breakdown of Value Sales for Veterinary Clinics, Other End-Users and Hospitals for the Years 2015, 2025 & 2030
  • TABLE 368: UAE Recent Past, Current & Future Analysis for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 369: UAE Historic Review for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 370: UAE 15-Year Perspective for Rabies Vaccine by Prophylaxis Type - Percentage Breakdown of Value Sales for Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis for the Years 2015, 2025 & 2030
  • TABLE 371: UAE Recent Past, Current & Future Analysis for Rabies Vaccine by Application - Human and Animal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 372: UAE Historic Review for Rabies Vaccine by Application - Human and Animal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 373: UAE 15-Year Perspective for Rabies Vaccine by Application - Percentage Breakdown of Value Sales for Human and Animal for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 374: Rest of Middle East Recent Past, Current & Future Analysis for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 375: Rest of Middle East Historic Review for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 376: Rest of Middle East 15-Year Perspective for Rabies Vaccine by Product Type - Percentage Breakdown of Value Sales for Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 377: Rest of Middle East Recent Past, Current & Future Analysis for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 378: Rest of Middle East Historic Review for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 379: Rest of Middle East 15-Year Perspective for Rabies Vaccine by End-user - Percentage Breakdown of Value Sales for Veterinary Clinics, Other End-Users and Hospitals for the Years 2015, 2025 & 2030
  • TABLE 380: Rest of Middle East Recent Past, Current & Future Analysis for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 381: Rest of Middle East Historic Review for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 382: Rest of Middle East 15-Year Perspective for Rabies Vaccine by Prophylaxis Type - Percentage Breakdown of Value Sales for Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis for the Years 2015, 2025 & 2030
  • TABLE 383: Rest of Middle East Recent Past, Current & Future Analysis for Rabies Vaccine by Application - Human and Animal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 384: Rest of Middle East Historic Review for Rabies Vaccine by Application - Human and Animal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 385: Rest of Middle East 15-Year Perspective for Rabies Vaccine by Application - Percentage Breakdown of Value Sales for Human and Animal for the Years 2015, 2025 & 2030
• AFRICA
  • Rabies Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 386: Africa Recent Past, Current & Future Analysis for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 387: Africa Historic Review for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 388: Africa 15-Year Perspective for Rabies Vaccine by Product Type - Percentage Breakdown of Value Sales for Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 389: Africa Recent Past, Current & Future Analysis for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 390: Africa Historic Review for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 391: Africa 15-Year Perspective for Rabies Vaccine by End-user - Percentage Breakdown of Value Sales for Veterinary Clinics, Other End-Users and Hospitals for the Years 2015, 2025 & 2030
  • TABLE 392: Africa Recent Past, Current & Future Analysis for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 393: Africa Historic Review for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 394: Africa 15-Year Perspective for Rabies Vaccine by Prophylaxis Type - Percentage Breakdown of Value Sales for Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis for the Years 2015, 2025 & 2030
  • TABLE 395: Africa Recent Past, Current & Future Analysis for Rabies Vaccine by Application - Human and Animal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 396: Africa Historic Review for Rabies Vaccine by Application - Human and Animal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 397: Africa 15-Year Perspective for Rabies Vaccine by Application - Percentage Breakdown of Value Sales for Human and Animal for the Years 2015, 2025 & 2030

IV. COMPETITION